Author Correction: Blocking Zika virus vertical transmission author-correction (Scientific Reports DOI: 10.1038/s41598-018-19526-4);Blocking Zika virus vertical transmission

Scientific Reports

Volumn 8, Issue 1, 2018, Pages

  Mesci, Pinar ^a   Macia, Angela ^a   Moore, Spencer M ^a   Shiryaev, Sergey A ^b   Pinto, Antonella ^b   Huang, Chun Teng ^b   Tejwani, Leon ^a   Fernandes, Isabella R ^a   Suarez, Nicole A ^a   Kolar, Matthew J ^c   Montefusco, Sandro ^d   Rosenberg, Scott C ^e,f   Herai, Roberto H ^g   Cugola, Fernanda R ^h   Russo, Fabiele B ^h   Sheets, Nicholas ⁱ   Saghatelian, Alan ^c   Shresta, Sujan ⁱ   Momper, Jeremiah D ^d   Siqueira Neto, Jair L ^d   Corbett, Kevin D ^e   Beltrão Braga, Patricia C B ^h   Terskikh, Alexey V ^b   Muotri, Alysson R ^a   more..

^a RADY CHILDREN'S HOSPITAL   (United States)

^b BURNHAM INSTITUTE   (United States)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e LUDWIG INSTITUTE FOR CANCER RESEARCH   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g PONTIFICAL CATHOLIC UNIVERSITY OF PARANÁ   (Brazil)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85040820674     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-26959-4     Document Type: Erratum

References (74)

1. Campos, G. S., Bandeira, A. C. & Sardi, S. I. Zika virus outbreak, Bahia, Brazil. Emerg. Infect. Dis. 21, 1885-1886 (2015).
2. Mlakar, J. et al. Zika Virus Associated with Microcephaly. N. Engl. J. Med. 374, 951-8 (2016).
3. van der Linden, V. et al. Description of 13 Infants Born During October 2015-January 2016 With Congenital Zika Virus Infection Without Microcephaly at Birth-Brazil. MMWR. Morb. Mortal. Wkly. Rep. 65, 1343-1348 (2016).
4. Xu, M. et al. Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen. Nat. Med. 22, 1101-1107 (2016).
5. Retallack, H. et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc. Natl. Acad. Sci. USA 113, 201618029 (2016).
6. Barrows, N. J. et al. A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell Host Microbe 20, 259-270 (2016).
7. Abbink, P. et al. Protective efficacy of multiple vaccine platforms against Zika virus challenge in rhesus monkeys. Science (2016). doi:10. 1126/science. aah6157
8. Larocca, R. A. et al. Vaccine protection against Zika virus from Brazil. Nature, https://doi. org/10. 1038/nature18952 (2016).
9. Reefhuis, J. et al. Projecting Month of Birth for At-Risk Infants after Zika Virus Disease Outbreaks. Emerg. Infect. Dis. 22, 828-32 (2016).
10. Sacramento, C. Q. et al. The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication. Sci. Rep. 7, 40920 (2017).
11. Onorati, M. et al. Zika Virus Disrupts Phospho-TBK1 Localization and Mitosis in Human Neuroepithelial Stem Cells and Radial Glia. Cell Rep. 16, 2576-2592 (2016).
12. Bullard-Feibelman, K. M. et al. The FDA-approved drug sofosbuvir inhibits Zika virus infection. Antiviral Res. 137, 134-140 (2017).
13. Ferreira, A. C. et al. Sofosbuvir protects Zika virus-infected mice from mortality, preventing short-and long-term sequelae. Sci. Rep. 7, 9409 (2017).
14. Sulkowski, M. S. et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N. Engl. J. Med. 370, 211-21 (2014).
15. Gentile, I., Maraolo, A. E., Buonomo, A. R., Zappulo, E. & Borgia, G. The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opin. Drug Discov. 10, 1363-77 (2015).
16. Toussaint-Miller, K. A. & Andres, J. Treatment Considerations for Unique Patient Populations With HCV Genotype 1 Infection. Ann. Pharmacother. 49, 1015-30 (2015).
17. Elfiky, A. A., Elshemey, W. M., Gawad, W. A. & Desoky, O. S. Molecular modeling comparison of the performance of NS5b polymerase inhibitor (PSI-7977) on prevalent HCV genotypes. Protein J. 32, 75-80 (2013).
18. Xu, D. et al. Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing. PLoS Med. 11, e1001628 (2014).
19. Li, C. et al. Zika Virus Disrupts Neural Progenitor Development and Leads to Microcephaly in Mice. Cell Stem Cell 19, 1-7 (2016).
20. Souza, B. S. F. et al. Zika virus infection induces mitosis abnormalities and apoptotic cell death of human neural progenitor cells. Sci. Rep. 6, 39775 (2016).
21. Cugola, F. R. et al. The Brazilian Zika virus strain causes birth defects in experimental models. Nature 1-15, https://doi. org/10. 1038/ nature18296 (2016).
22. Lindenbach, B. D. & Rice, C. M. In Fields virology, 5th Edition (2007).
23. Appleby, T. C. et al. Viral replication. Structural basis for RNA replication by the hepatitis C virus polymerase. Science 347, 771-5 (2015).
24. Garcez, P. P. et al. Zika virus impairs growth in human neurospheres and brain organoids. Science aaf6116 https://doi. org/10. 1126/ science. aaf6116 (2016).
25. Dang, J. et al. Zika Virus Depletes Neural Progenitors in Human Cerebral Organoids through Activation of the Innate Immune Receptor TLR3. Cell Stem Cell, 1-8, https://doi. org/10. 1016/j. stem. 2016. 04. 014 (2016).
26. Tang, H. et al. Zika Virus Infects Human Cortical Neural Progenitors and Attenuates Their Growth. Cell Stem Cell 18, 587-590 (2016).
27. Wu, K.-Y. et al. Vertical transmission of Zika virus targeting the radial glial cells affects cortex development of offspring mice. Cell Res., https://doi. org/10. 1038/cr. 2016. 58 (2016).
28. Reznik, S. E. & Ashby, J. C. R. Sofosbuvir: an anti-viral drug with potential efficacy against Zika infection. Int. J. Infect. Dis. 55, In press (2016).
29. Mesci, P. et al. Modeling neuro-immune interactions during Zika virus infection. Hum. Mol. Genet. https://doi. org/10. 1093/hmg/ ddx382 (2017).
30. Zmurko, J. et al. Substrate selectivity of Dengue and Zika virus NS5 polymerase towards 2?-modified nucleotide analogues. Antiviral Res. 55, In press (2016).
31. Kataoka, S. et al. Immunologic aspects of the nonobese diabetic (NOD) mouse. Abnormalities of cellular immunity. Diabetes 32, 247-53 (1983).
32. Zmurko, J. et al. The Viral Polymerase Inhibitor 7-Deaza-2?-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model. PLoS Negl. Trop. Dis. 10, e0004695-e0004695 (2016).
33. Lazear, H. M. et al. A Mouse Model of Zika Virus Pathogenesis Cell Host & Microbe Resource A Mouse Model of Zika Virus Pathogenesis. Cell Host Microbe 19, 1-11 (2016).
34. Rossi, S. L. et al. Characterization of a Novel Murine Model to Study Zika Virus. Am. J. Trop. Med. Hyg. 94, ajtmh. 16-0111 (2016).
35. Aliota, M. T. et al. Characterization of Lethal Zika Virus Infection in AG129 Mice. PLoS Negl. Trop. Dis. 10, e0004682 (2016).
36. Nair, A. B. & Jacob, S. A simple practice guide for dose conversion between animals and human. J. basic Clin. Pharm. 7, 27-31 (2016).
37. Gilead Sciences, I. Highlights of prescribing information. United States Food & Drug Administration Available at: https://www. accessdata. fda. gov/drugsatfda-docs/label/2013/204671s000lbl. pdf (2013).
38. Shiryaev, S. A. et al. Repurposing of the anti-malaria drug chloroquine for Zika Virus treatment and prophylaxis. Sci. Rep. 7, 15771 (2017).
39. Styer, L. M. et al. Mosquitoes inoculate high doses of West Nile virus as they probe and feed on live hosts. PLoS Pathog. 3, 1262-1270 (2007).
40. Barrows, N. J. et al. A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection. Cell Host Microbe 20, 259-70 (2016).
41. Oliveira, D. B. L. et al. Prolonged Shedding of Zika Virus Associated with Congenital Infection. N. Engl. J. Med. 375, 1202-1204 (2016).
42. Ginhoux, F. et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 330, 841-5 (2010).
43. Mandelbrot, L. et al. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin. Infect. Dis. 61, 1715-25 (2015).
44. Pasternak, B. & Hviid, A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA 304, 859-66 (2010).
45. Ellis, C. Center for drug evaluation and research 204671Orig1s000. Pharmacology Review(S) (2013).
46. Nishiura, H. et al. A theoretical estimate of the risk of microcephaly during pregnancy with Zika virus infection. Epidemics 15, 66-70 (2016).
47. Bhatia, H. K., Singh, H., Grewal, N. & Natt, N. K. Sofosbuvir: A novel treatment option for chronic hepatitis Cinfection. J. Pharmacol. Pharmacother. 5, 278-284 (2014).
48. Broutet, N. et al. Zika Virus as a Cause of Neurologic Disorders. N. Engl. J. Med. 374, 1506-9 (2016).
49. Carteaux, G. et al. Zika Virus Associated with Meningoencephalitis. N. Engl. J. Med. 374, 1595-6 (2016).
50. Furtado, J. M., Espósito, D. L., Klein, T. M., Teixeira-Pinto, T. & da Fonseca, B. A. Uveitis Associated with Zika Virus Infection. N. Engl. J. Med. 375, 394-6 (2016).
51. Mécharles, S. et al. Acute myelitis due to Zika virus infection. Lancet (London, England) 387, 1481 (2016).
52. Eyer, L. et al. Nucleoside inhibitors of Zika virus. J. Infect. Dis. (2016). doi:10. 1093/infdis/jiw226
53. Potisopon, S., Ferron, F., Fattorini, V. & Selisko, B. & Canard, B. Substrate selectivity of Dengue and Zika virus NS5 polymerase towards 2?-modified nucleotide analogues. Antiviral Res. 140, 25-36 (2016).
54. Balm, M. N. D. et al. A diagnostic polymerase chain reaction assay for Zika virus. J. Med. Virol. 84, 1501-5 (2012).
55. Lanciotti, R. S. et al. Genetic and serologic properties of Zika virus associated with an epidemic, Yap State, Micronesia, 2007. Emerg. Infect. Dis. 14, 1232-1239 (2008).
56. Chailangkarn, T. et al. A human neurodevelopmental model for Williams syndrome. Nature, https://doi. org/10. 1038/nature19067 (2016).
57. Marchetto, M. C. N. et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143, 527-39 (2010).
58. Marchetto, M. C. et al. Altered proliferation and networks in neural cells derived from idiopathic autistic individuals. Mol. Psychiatry, https://doi. org/10. 1038/mp. 2016. 95 (2016).
59. Rezk, M. R., Basalious, E. B. & Karim, I. A. Development of a sensitive UPLC-ESI-MS/MS method for quantification of sofosbuvir and its metabolite, GS-331007, in human plasma: Application to a bioequivalence study. J. Pharm. Biomed. Anal. 114, 97-104 (2015).
60. Jackowiak, P. et al. Phylogeny and molecular evolution of the hepatitis C virus. Infect. Genet. Evol. 21, 67-82 (2014).
61. Smith, D. B. et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 59, 318-27 (2014).
62. Enfissi, A., Codrington, J., Roosblad, J., Kazanji, M. & Rousset, D. Zika virus genome from the Americas. Lancet (London, England) 387, 227-8 (2016).
63. Pickett, B. E. et al. ViPR: an open bioinformatics database and analysis resource for virology research. Nucleic Acids Res. 40, D593-8 (2012).
64. Balakrishnan, A., Butte, D. K. & Jadhav, S. M. Complete Genome Sequence of West Nile Virus Isolated from Alappuzha District, Kerala, India. Genome Announc. 1, 4-5 (2013).
65. Singha, H. et al. Complete genome sequence analysis of Japanese encephalitis virus isolated from a horse in India. Arch. Virol. 158, 113-122 (2013).
66. Naveca, F. G. et al. Complete Genome Sequence of a Dengue Virus Serotype 4 Strain Isolated in Roraima, Brazil. J. Virol. 86, 1897-1898 (2012).
67. Calvet, G. et al. Case Report of detection of Zika virus genome in amniotic fluid of affected fetuses: association with microcephaly outbreak in Brazil. Lancet Infect. Dis. 3099, In press (2016).
68. Lu, L. et al. Complete genomes of hepatitis C virus (HCV) subtypes 6c, 6l, 6o, 6p and 6q: completion of a full panel of genomes for HCV genotype 6. J. Gen. Virol. 88, 1519-1525 (2007).
69. Dereeper, A. et al. Phylogeny. fr: robust phylogenetic analysis for the non-specialist. Nucleic Acids Res. 36, W465-9 (2008).
70. Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792-7 (2004).
71. Castresana, J. Selection of Conserved Blocks from Multiple Alignments for Their Use in Phylogenetic Analysis. Mol. Biol. Evol 17, 540-552 (2000).
72. Guindon, S. & Gascuel, O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst. Biol. 52, 696-704 (2003).
73. Chevenet, F., Brun, C., Bañuls, A.-L., Jacq, B. & Christen, R. TreeDyn: towards dynamic graphics and annotations for analyses of trees. BMC Bioinformatics 7, 439 (2006).
74. Waterhouse, A. M., Procter, J. B., Martin, D. M. A., Clamp, M. & Barton, G. J. Jalview Version 2-a multiple sequence alignment editor and analysis workbench. Bioinformatics 25, 1189-1191 (2009).